Dr. Arthur Suckow, CEO of DTx Pharma, a San Diego-based biotechnology company developing novel RNA-based therapeutics to treat the genetic drivers of rare diseases, discusses the current challenges with RNA therapeutics and the development of a platform called FALCON™ (Fatty Acid Ligand Conjugated OligoNucleotide).
Dr. Suckow founded DTx Pharma in 2017. An innovative leader in drug discovery, he previously worked on the ophthalmology, diabetes, and NASH programs at Regulus Therapeutics, at the MedImmune arm of AstraZeneca, and in the Diabetes Drug Discovery program at Johnson & Johnson. Dr. Suckow received his BS from the University of Delaware and his PhD from University of California, San Diego. He has received numerous awards including a Beckman Fellowship, a NSF graduate research fellowship, and a BIOCOM catalyst award.